23 September 2021
Remdesivir (trade name Remdeform) was included in all inpatient treatment regiments in the 12th version of the temporary guidelines for the treatment of patients with COVID-19 approved by the Ministry of Health of the Russian Federation on September 21, as Pharmasintez, the manufacturer of the drug, reports.
“The change from the 11th version of the recommendations is that it has become possible to prescribe remdesivir to patients with a high comorbidity index who have a mild course of the disease and are treated in inpatient settings,” the report says.
It is noted that the section “Pathogenetic treatment” has been completely revised taking into account the accumulated experience of COVID-19 treatment: the information about possible combinations of drugs was added, including those that include remdesivir. The regimens for patients with moderate and severe course of the disease were revised: etiotropic therapy was optimized towards the use of more effective approaches (Remdesivir, human anti-COVID-19 immunoglobulin).
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024